Letter to Shareholders Details CardioComm Solutions' 2014 Milestones

Posted by Laura Swartz

December 19, 2013 at 11:21 AM

CardioComm Solutions, Inc. (EKG-TSX.V), a provider of innovative software solutions for information management systems in cardiovascular medicine and telemedicine, issued a letter to shareholders and friends yesterday detailing the company’s progress and goals to date. 

The full letter can be viewed on CardioComm’s website, but here are some of the highlights… 

Read More

Topics: CardioComm Solutions

ISCO Receives Award for its Metabolic Liver Disease Program

Posted by Samy Goldfarb

December 18, 2013 at 10:49 AM

 

Read More

Topics: ISCO, human induced pluripotent stem cell

PBIO: Investor Call with Merriman Capital on Thurs., Dec. 12 at 4:30p

Posted by Laura Swartz

December 11, 2013 at 9:06 PM

On Thursday, December 12th, Merriman Capital, Inc. will host an investor call for Pressure BioSciences, Inc. (PBIO) at 4:30 p.m. EST. Investors and any other interested parties should dial into this call for an update on PBIO’s recent achievements, such as the Company’s record revenue in the third quarter 2013, and forthcoming milestones. A Q&A session will also be available following the call. Pressure BioSciences’ CEO Richard T. Schumacher, Board Chairman Jeffrey N. Peterson, and other board members Mr. Vito Mangiardi, Mr. Kevin Pollack, and Dr. Mickey Urdea will join in the Q&A.  

Conference Call Details

Read More

Topics: Pressure BioSciences

ISCO Announces Major Advance in iPS Stem Cell Technology

Posted by Samy Goldfarb

December 9, 2013 at 11:54 AM

International Stem Cell Corporation (ISCO:OTCQB), a biotechnology company developing novel stem cell-based therapies, announced the development of a new method for the derivation of human induced pluripotent stem cells (iPS) that utilizes a novel protein-based reprogramming process. The Company believes that the new method is a safer and more efficient alternative to older iPS reprogramming techniques, and represents a step forward in the ability to use iPS clinically.

Read More

Topics: ISCO, human induced pluripotent stem cell

AtheroNova Announces Phase I Enrollment Complete for Clinical Trial of AHRO-001 in Treating Atherosclerosis

Posted by Karen Goldfarb

December 5, 2013 at 1:14 PM

AtheroNova Inc. announced today a significant milestone in completing the active treatment portion of its Phase 1 clinical trial with its lead compound, AHRO-001. The objective of the Phase I study is to evaluate AHRO-001’s safety, tolerability, and pharmacokinetics in volunteers who are healthy. This clinical study is being conducted in Russia with AtheroNova's licensing partner, OOO CardioNova.

The design of the Phase 1 study is to characterize the safety of AHRO-001 through three dose ranges and possible pharmacokinetics, with a planned enrollment of 54 subjects. This multi-center, randomized, double-blind, placebo-controlled, single and multiple dose escalation, is the first-in-human study of AHRO-001 administered via oral tablet to healthy adult volunteers at sites in Moscow and St. Petersburg, Russia. All subjects have been dosed and received either placebo or AHRO-001 in doses ranging from 18.75 mg/kg to 37.5 mg/kg per day. Top line data is expected to be announced in the first quarter of 2014.

Read More

Topics: AtheroNova

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic